Earnings

Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 Est

Jul 23, 2026 · 06:46 AM ET· updated 3h ago

Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 analyst estimate..

Why It Matters

Quest Diagnostics says it will make more profit per share next year than it thought before—a sign the company is doing better than expected. When a company raises its profit outlook, it can mean things are going well, so it's worth watching to see if the company keeps delivering on its new promise.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

DGX231.78

+21.95 (+10.46%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.